Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Samsung Biologics Co Ltd    A207940   KR7207940008

SAMSUNG BIOLOGICS CO LTD

(A207940)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Samsung Biologics, Biogen Venture Gets FDA OK for Humira Biosimilar

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/24/2019 | 11:15am EDT

By Colin Kellaher

Samsung Bioepis Co. on Wednesday said the U.S. Food and Drug Administration approved Hadlima, a biosimilar of AbbVie blockbuster drug Humira, for several inflammatory conditions.

Samsung Bioepis, a joint venture between Korea's Samsung BioLogics Co and Biogen of the U.S., said the approval covers the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.

Humira, the world's biggest-selling drug, had nearly $20 billion in global sales in 2018, accounting for about 61% of AbbVie's total revenue.

Sales of Humira biosimilars began in Europe late last year after a key AbbVie European patent expired, but a group of U.S. patents built up by AbbVie has prevented a U.S. launch.

Samsung Bioepis said Hadlima will launch in the U.S. after June 30, 2023, under a licensing agreement with AbbVie, adding that Merck & Co. (MRK) will commercialize the drug in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -0.46% 71.27 Delayed Quote.-22.69%
BIOGEN INC. -1.48% 235.17 Delayed Quote.-21.85%
MERCK AND COMPANY 0.62% 83.02 Delayed Quote.8.65%
SAMSUNG BIOLOGICS CO LTD End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAMSUNG BIOLOGICS CO LTD
08/29South Korea court ruling raises chance of Samsung heir's return to jail
RE
08/29SAMSUNG ELECTRONICS : South Korea's top court ruling on Samsung heir and ex-pres..
RE
08/22SAMSUNG ELECTRONICS : South Korea's top court to rule on Samsung heir's bribery ..
RE
08/22SAMSUNG ELECTRONICS : South Korea's top court to rule on Samsung heir's bribery ..
RE
07/24Samsung Biologics, Biogen Venture Gets FDA OK for Humira Biosimilar
DJ
06/24SAMSUNG ELECTRONICS : embroiled in multiple patent lawsuits in US
AQ
06/17Samsung scrambles to deal with growing uncertainties
AQ
06/14SAMSUNG ELECTRONICS : president grilled amid biotech accounting scandal
AQ
06/12SAMSUNG ELECTRONICS : president grilled about accounting scandal at biotech affi..
AQ
06/12SAMSUNG ELECTRONICS : president grilled about accounting scandal at biotech affi..
AQ
More news
Financials (KRW)
Sales 2019 576 B
EBIT 2019 43,6 B
Net income 2019 26,7 B
Finance 2019 213 B
Yield 2019 -
P/E ratio 2019 775x
P/E ratio 2020 96,9x
EV / Sales2019 36 324x
EV / Sales2020 24 011x
Capitalization 20 908 B
Chart SAMSUNG BIOLOGICS CO LTD
Duration : Period :
Samsung Biologics Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 316 000,00  KRW
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tae-Han Kim Chief Executive Officer & Director
Ho-Yeol Yoon Managing Director & Head-Operations Support
Dong-Joong Kim Director & Head-Management Support
Seok-Woo Jung Outside Director
Byeong-Cheol Yoon Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO LTD17 563
CSL LIMITED26.79%72 905
BIOGEN INC.-21.85%43 376
ALEXION PHARMACEUTICALS10.75%23 091
GRIFOLS19.61%18 170
BIOMARIN PHARMACEUTICAL INC.-11.33%13 549